Related Experiment Videos
Regression of left ventricular hypertrophy--are there differences between antihypertensive agents?
1Department of Medicine, University of Göteborg, Ostra Hospital, Sweden.
Insights
Left ventricular mass (LVM) reduction is key for cardiovascular health. ACE inhibitors show the most significant LVM reduction, suggesting improved antihypertensive therapy outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular mass (LVM) determined by echocardiography is a potent cardiovascular disease risk indicator.
- Regression of cardiac hypertrophy is a logical therapeutic goal, though its prognostic benefits require further establishment.
- Certain antihypertensive drug classes vary in their effectiveness for reversing left ventricular hypertrophy (LVH) despite similar blood pressure-lowering effects.
Purpose of the Study:
- To conduct a meta-analysis of clinical studies to evaluate the impact of different antihypertensive therapies on left ventricular mass (LVM).
- To compare the efficacy of various antihypertensive drug classes in reversing left ventricular hypertrophy (LVH).
Main Methods:
- Meta-analysis of 109 pharmacological antihypertensive therapy studies.
- Inclusion of studies with echocardiographically determined LVM.
- Analysis adjusted for study differences using ANCOVA to compare the effects of four first-line antihypertensive treatments.
Main Results:
- ACE inhibitors, beta-blockers, and calcium antagonists effectively reduce LVM through wall hypertrophy reversal, with ACE inhibitors showing the most pronounced effect.
- Diuretics primarily reduce LVM by decreasing left ventricular diameter.
- Significant differences in LVH reversal efficacy were observed among antihypertensive drug classes.
Conclusions:
- ACE inhibitors, beta-blockers, and calcium antagonists are effective in reducing left ventricular mass (LVM) by reversing hypertrophy.
- ACE inhibitors demonstrate the greatest efficacy in reducing LVM.
- The differential ability of antihypertensive agents to reverse LVH may impact patient prognosis, a hypothesis currently under investigation.
Abstract:
Echocardiographically determined left ventricular mass (LVM) is currently considered to be the most powerful risk indicator for cardiovascular disease, yielding prognostic information beyond that provided by the evaluation of traditional cardiovascular risk factors, high blood pressure included. It has been considered logical to try to obtain regression of cardiac hypertrophy, even though the risk-reducing implications of such a measure remain to be fully established. Experimental and clinical studies have shown that some classes of antihypertensive compounds are less effective than others in causing reversal of left ventricular hypertrophy (LVH) in spite of being similarly efficacious in lowering blood pressure. In order to extract the maximum amount of information from clinical studies, a meta-analysis was performed. This analysis included 109 treatment studies, each conformed to strict present rules. Only studies with pharmacological antihypertensive therapy and echocardiographically determined LVM were included. An analysis of the effect of the four first-hand antihypertensive treatment principles, adjusted for differences between studies with ANCOVA, showed that the ACE inhibitors, beta-blockers and calcium antagonists all reduce LVM by reversing wall hypertrophy and that the effect is most pronounced with ACE inhibitors. Diuretics reduce LVM mainly by a reduction in left ventricular diameter. If the difference in ability to reverse LVH, between ACE inhibitors and beta-blockers/diuretics would correspond to a difference in prognosis, then the outcome of antihypertensive therapy might be expected to improve. This hypothesis is currently under investigation.